nach oben

Journal of Clinical Immunology

Erschienen in:

01.03.2008

Treatment of Multiple Sclerosis with Methylprednisolone and Mitoxantrone Modulates the Expression of CXC Chemokine Receptors in PBMC

verfasst von: Bartosz Bielecki, Andzelika Mazurek, Paweł Wolinski, Andrzej Glabinski

Erschienen in: Journal of Clinical Immunology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Chemokines and their receptors are involved in the development of multiple sclerosis (MS). Methylprednisolone (MP) and mitoxantrone (MTX) are commonly used in the treatment of MS. In this study, we analyzed the expression of chemokine receptors CXCR1, CXCR2, CXCR3, CXCR4, and CXCR5 in peripheral blood mononuclear cells (PBMC) from MS patients before and after treatment with MP or MTX. We observed a significant upregulation of expression of CXCR1 and CXCR2 in untreated MS patients. Treatment of MS with MP stimulated further increase of expression of both receptors. Therapy for MS with MTX resulted in decrease of CXCR2 expression. There was a negative correlation between the expression of CXCR1 and CXCR2 and the cumulative dose of MTX received by patients. These results suggest that CXCR1 and CXCR2 may be involved in MS pathogenesis and that treatment of this disease with MP and MTX may influence expression of those receptors.

Compston A, Sadovnick AD. Epidemiology and genetics of multiple sclerosis. Curr Opin Neurol Neurosurg 1992;5:175–81.PubMed

Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 2006;354:942–55.PubMedCrossRef

Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683–747.PubMedCrossRef

Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–7.PubMedCrossRef

Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, Barde YA. Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. J Neurosci 2002;22:854–62.PubMed

Redford EJ, Kapoor R, Smith KJ. N-itric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120 Pt 12:2149–57.PubMedCrossRef

Wilkins A, Chandran S, Compston A. A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Glia 2001;36:48–57.PubMedCrossRef

Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610–21.PubMedCrossRef

Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123–8.PubMedCrossRef

10.

White MV, Yoshimura T, Hook W, Kaliner MA, Leonard EJ. Neutrophil attractant/activation protein-1 (NAP-1) causes human basophil histamine release. Immunol Lett 1989;22:151–4.PubMedCrossRef

11.

Warringa RA, Koenderman L, Kok PT, Kreukniet J, Bruijnzeel PL. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Blood 1991;77:2694–700.PubMed

12.

Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989;243:1464–6.PubMedCrossRef

13.

Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348–57.PubMedCrossRef

14.

Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991;253:1278–80.PubMedCrossRef

15.

Moser B, Barella L, Mattei S, Schumacher C, Boulay F, Colombo MP, et al. Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem J 1993;294 Pt 1:285–92.PubMed

16.

Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991;253:1280–3.PubMedCrossRef

17.

Unemori EN, Amento EP, Bauer EA, Horuk R. Melanoma growth-stimulatory activity/GRO decreases collagen expression by human fibroblasts. Regulation by C-X-C but not C-C cytokines. J Biol Chem 1993;268:1338–42.PubMed

18.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–7.PubMedCrossRef

19.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–6.PubMedCrossRef

20.

Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000;123 Pt 6:1092–101.PubMedCrossRef

21.

Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63–6.PubMedCrossRef

22.

Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1–10.PubMedCrossRef

23.

Kent SJ, Karlik SJ, Rice GP, Horner HC. A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 1995;5:535–40.PubMedCrossRef

24.

Hulkower K, Brosnan CF, Aquino DA, Cammer W, Kulshrestha S, Guida MP, et al. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J Immunol 1993;150:2525–33.PubMed

25.

Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993;7:592–600.PubMed

26.

Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:167–76.PubMedCrossRef

27.

Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol 2003;13:38–51.PubMedCrossRef

28.

Glabinski AR, Tani M, Tuohy VK, Tuthill RJ, Ransohoff RM. Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun 1995;9:315–30.PubMedCrossRef

29.

Glabinski AR, Tuohy VK, Ransohoff RM. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998;5:166–71.PubMedCrossRef

30.

Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM. Synchronous synthesis of alpha- and beta- chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997; 150:617–30.

31.

Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873–8.PubMedCrossRef

32.

Boven LA, Montagne L, Nottet HS, De Groot CJ. Macrophage inflammatory protein-1 alpha (MIP-1 alpha), MIP-1 beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin Exp Immunol 2000;122:257–63.PubMedCrossRef

33.

Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998;84:238–49.PubMedCrossRef

34.

Bonecchi R, Facchetti F, Dusi S, Luini W, Lissandrini D, Simmelink M, et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol 2000;164:3862–9.PubMed

35.

Puma C, Danik M, Quirion R, Ramon F, Williams S. The chemokine interleukin-8 acutely reduces Ca(2+) currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J Neurochem 2001;78:960–71.PubMedCrossRef

36.

Danik M, Puma C, Quirion R, Williams S. Widely expressed transcripts for chemokine receptor CXCR1 in identified glutamatergic, gamma-aminobutyric acidergic, and cholinergic neurons and astrocytes of the rat brain: a single-cell reverse transcription-multiplex polymerase chain reaction study. J Neurosci Res 2003;74:286–95.PubMedCrossRef

37.

Omari KM, John GR, Sealfon SC, Raine CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005;128:1003–15.PubMedCrossRef

38.

Omari KM, John G, Lango R, Raine CS. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006;53:24–31.PubMedCrossRef

39.

Glabinski AR, O’Bryant S, Selmaj K, Ransohoff RM. CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 2000;917:135–44.PubMedCrossRef

40.

Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000;192:1545–52.PubMedCrossRef

41.

Hardtke S, Ohl L, Forster R. Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. Blood 2005;106:1924–31.PubMedCrossRef

42.

Lee BP, Chen W, Shi H, Der SD, Forster R, Zhang L. CXCR5/CXCL13 interaction is important for double-negative regulatory T cell homing to cardiac allografts. J Immunol 2006;176:5276–83.PubMed

43.

Ansel KM, Heyzer-Williams LJ, Ngo VN, Heyzer-Williams MG, Cyster JG. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med 1999;190:1123–34.PubMedCrossRef

44.

Moser B, Ebert L. Lymphocyte traffic control by chemokines: follicular B helper T cells. Immunol Lett 2003;85:105–12.PubMedCrossRef

45.

Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129:200–11.PubMedCrossRef

46.

Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001;58:91–7.PubMedCrossRef

47.

Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998;85:122–30.PubMedCrossRef

48.

Gelati M, Corsini E, De Rossi M, Masini L, Bernardi G, Massa G, et al. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 2002;59:774–80.PubMedCrossRef

49.

Vanderheyde N, Verhasselt V, Goldman M, Willems F. Inhibition of human dendritic cell functions by methylprednisolone. Transplantation 1999;67:1342–7.PubMedCrossRef

50.

Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192–8.PubMedCrossRef

51.

Sorensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001;8:665–72.PubMedCrossRef

52.

Bartosik-Psujek H, Stelmasiak Z. Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse. Eur Neurol 2004;52:237–41.PubMedCrossRef

53.

Elovaara I, Kuusisto H, Paalavuo R, Sarkijarvi S, Lehtimaki T, Huhtala H, et al. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta Neurol Scand 2006;113:163–6.PubMedCrossRef

54.

Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 2002;127:165–71.PubMedCrossRef

55.

Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, et al. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol 2004;155:161–71.PubMedCrossRef

56.

Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand 2004;109:390–2.PubMedCrossRef

57.

Rosenberg LS, Carvlin MJ, Krugh TR. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. Biochemistry 1986;25:1002–8.PubMedCrossRef

58.

Lenk H, Muller U, Tanneberger S. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 1987;7:1257–64.PubMed

59.

Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986;137:727–32.PubMed

60.

Fidler JM, DeJoy SQ, Smith FR III, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986;136:2747–54.PubMed

61.

Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986;13:175–81.PubMedCrossRef

62.

Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985;35:35–42.PubMedCrossRef

63.

Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C. Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003;49:137–41.PubMedCrossRef

64.

Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139:152–8.PubMedCrossRef

65.

Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128–37.PubMedCrossRef

66.

Pelfrey CM, Cotleur AC, Zamor N, Lee JC, Fox RJ. Immunological studies of mitoxantrone in primary progressive MS. J Neuroimmunol 2006;175:192–9.PubMedCrossRef

Titel: Treatment of Multiple Sclerosis with Methylprednisolone and Mitoxantrone Modulates the Expression of CXC Chemokine Receptors in PBMC
verfasst von: Bartosz Bielecki
Andzelika Mazurek
Paweł Wolinski
Andrzej Glabinski
Publikationsdatum: 01.03.2008
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 2/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-007-9142-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Treatment of Multiple Sclerosis with Methylprednisolone and Mitoxantrone Modulates the Expression of CXC Chemokine Receptors in PBMC

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Blimp-1 Connects the Intrinsic and Extrinsic Regulation of T Cell Homeostasis

Association and Expression Study of PRKCH Gene in a French Caucasian Population with Rheumatoid Arthritis

Thymopoiesis, Regulatory T Cells, and TCRVβ Expression in Thymoma With and Without Myasthenia Gravis, and Modulatory Effects of Steroid Therapy

DNA Methylation and the Expression of IL-4 and IFN-γ Promoter Genes in Patients with Bronchial Asthma

Resistance to Apoptosis and Expansion of Regulatory T Cells in Relation to the Detection of Circulating Tumor Cells in Patients with Metastatic Epithelial Cancer

Inhibition of Airway Allergic Disease by Co-Administration of Flagellin with Allergen

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin